Amgen Inc. (AMGN) stock forecast & analysis
439.26
NasdaqGS · USDDelayed by 15 minutes
Down: -8.02, -1.8%
439.26Unchanged: +0.00, +0.0%
1 analysis
Latest analysis: · verdict locked
- Open
- 443.44
- Previous close
- 447.28
- Day range
- 439.07 – 444.59
- 52-week range
- 288.00 – 450.98
- Volume (shares)
- 1.81M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 540.63M
- P/E ratio
- 27.28
- Dividend yield
- 2.29%
- Beta
- 0.41
- Market cap
- 237.48B
Market Scanner’s AI analysis of Amgen Inc. (AMGN), updated October 2026: Amgen's Imdelltra data and technical strength were key discussion points in recent analyses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Amgen Inc. (AMGN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Amgen's Imdelltra data and technical strength were key discussion points in recent analyses.
Recent analyses covered Amgen's technical price position, noting the stock is trading above its 50-day and 200-day moving averages with rising trends. The company's drug Imdelltra was highlighted as a fundamental catalyst, with news reporting a significant reduction in mortality risk for a specific cancer treatment. Discussions also touched on the stock's valuation relative to its 52-week range and upcoming earnings.
AMGN news & sentiment
News coverage focused on the potential impact of Imdelltra data, with some discussion questioning if the positive results were already reflected in the stock price. Social media sentiment was not covered in the provided notes.
AMGN technical picture
Amgen's price sits above rising 50-day and 200-day SMAs, forming a bullish stack. Short-term momentum is positive, with the 10-day EMA below the close, and the MACD histogram shows re-accelerating momentum.
Fundamentals
The analysis covered Amgen's valuation, noting its price is near its 52-week high and trading above key moving averages. Upcoming earnings were also mentioned as a near-term event.
Factors discussed — upside
- Price above rising 50-day and 200-day SMAs, indicating a bullish stack.
- Short-term momentum indicated by the 10-day EMA below the close.
- MACD histogram shows momentum re-accelerating.
- Imdelltra data showed a 58% reduction in death risk in first-line extensive-stage small cell lung cancer.
- Stock price is 52.5% above its 52-week low.
Factors discussed — risks
- Imdelltra news release is company-provided framing and requires further validation against trial data.
- Companion news piece questioned whether Imdelltra's positive data is already priced in.
- Technical price action
- Fundamental catalysts
- Valuation
- Drug development
Summary updated .
AMGN technical indicators
Common technical indicators for AMGN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 417.26 | Price above |
| 10-day exponential moving average | 432.14 | Price above |
| Relative strength index (14-day) | 60.82 | Neutral |
| MACD line (12/26/9) | 8.8582 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 394.71 – 447.93 | Price inside the bands |
Analyses
Recent AMGN.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-25 AMGN.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Amgen Inc.?
- The bull case centered on positive clinical data for Imdelltra, showing a significant reduction in mortality risk for extensive-stage small cell lung cancer, and a strong technical setup with the stock trading above key moving averages and showing re-accelerating momentum. The stock's price also showed considerable strength relative to its 52-week low.
- What are the risks for Amgen Inc.?
- Risks discussed included the need for further validation of the Imdelltra data against trial specifics and questions about whether the positive news was already priced into the stock.
- Is Amgen Inc. bullish or bearish?
- Recent AI analyses of Amgen Inc. examined factors on both sides. Discussed upside: The bull case centered on positive clinical data for Imdelltra, showing a significant reduction in mortality risk for extensive-stage small cell lung cancer, and a strong technical setup with the stock trading above key moving averages and showing re-accelerating momentum. The stock's price also showed considerable strength relative to its 52-week low. Discussed risks: Risks discussed included the need for further validation of the Imdelltra data against trial specifics and questions about whether the positive news was already priced into the stock. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Amgen Inc.?
- News coverage focused on the potential impact of Imdelltra data, with some discussion questioning if the positive results were already reflected in the stock price. Social media sentiment was not covered in the provided notes.
- How does Market Scanner analyse Amgen Inc.?
- Every analysis of Amgen Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Amgen Inc.?
The bull case centered on positive clinical data for Imdelltra, showing a significant reduction in mortality risk for extensive-stage small cell lung cancer, and a strong technical setup with the stock trading above key moving averages and showing re-accelerating momentum. The stock's price also showed considerable strength relative to its 52-week low.
What are the risks for Amgen Inc.?
Risks discussed included the need for further validation of the Imdelltra data against trial specifics and questions about whether the positive news was already priced into the stock.
Is Amgen Inc. bullish or bearish?
Recent AI analyses of Amgen Inc. examined factors on both sides. Discussed upside: The bull case centered on positive clinical data for Imdelltra, showing a significant reduction in mortality risk for extensive-stage small cell lung cancer, and a strong technical setup with the stock trading above key moving averages and showing re-accelerating momentum. The stock's price also showed considerable strength relative to its 52-week low. Discussed risks: Risks discussed included the need for further validation of the Imdelltra data against trial specifics and questions about whether the positive news was already priced into the stock. These are descriptive observations, not a recommendation.
What is the latest sentiment on Amgen Inc.?
News coverage focused on the potential impact of Imdelltra data, with some discussion questioning if the positive results were already reflected in the stock price. Social media sentiment was not covered in the provided notes.
How does Market Scanner analyse Amgen Inc.?
Every analysis of Amgen Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh AMGN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.